Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 1326 - 1350 of 1988 in total

GDC-0917

CUDC-427 has been used in trials studying the treatment of LYMPHOMA and Solid Cancers.
Investigational

GDC-0152

GDC-0152 has been used in trials studying the treatment of Solid Cancers.
Investigational

CYNK-001

CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.
Investigational

BSK02

BSK02 is a Sperm Protein-17 oral microparticle vaccine
Investigational

ETBX-011

ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).
Investigational

ETBX-021

Investigational

ETBX-061

Investigational

AVR-RD-01

AVR-RD-01 is an investigational ex vivo lentiviral gene therapy developed by AVROBIO Inc. It consists of autologous CD34+ cells that transduced with Lentiviral Vector/alpha-galactosidase A (AGA) encoding for the human AGA complementary deoxyribonucleic acid (cDNA) sequence. AVR-RD-01 is being investigated for Fabry Disease.[L45963, L45968]
Investigational

ABSK-012

Investigational

PLG-0206

PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections.
Investigational

BRG01

BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.
Investigational

LAVA-051

LAVA-051 is a humanized Vγ9Vδ2-T cell-engaging bispecific antibody.
Investigational

OSSM-007

OSSM-007 consists of interferon-gamma primed allogeneic mesenchymal stem cells.
Investigational

AVR-RD-05

AVR-RD-05 is a gene therapy comprising genetically modified autologous stem cells transduced ex vivo with a lentiviral vector encoding the human iduronate-2-sulfatase (IDS) enzyme. It is under investigation for the treatment of Hunter Syndrome (Mucopolysaccharidosis Type II, MPSII).
Investigational

Strychnine

Experimental
Matched Iupac: … (1R,11S,18S,20R,21R,22S)-12-oxa-8,17-diazaheptacyclo[15.5.2.0^{1,18}.0^{2,7}.0^{8,22}.0^{11,21}.0^{15,20 …
Matched Salts cas: … 66-32-0 ... 60-41-3 …

GPI-0100

GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response. The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy.
Investigational

IOWH-032

Iowh032 has been investigated for the treatment of Cholera, Diarrhea, and Secretory Diarrhea.
Investigational

GDC-0349

GDC-0349 has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Solid Tumor.
Investigational

GDC-0425

GDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma).
Investigational

IQP-0528

IQP-0528 is under investigation in clinical trial NCT03082690 (ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study).
Investigational

CODA-001

CODA-001 is under investigation in clinical trial NCT01165450 (Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects).
Investigational

PCLX-001

PCLX-001 is a first-in-kind N-Myristoyltransferase (NMT) inhibitor being developed by Pacylex Pharmaceuticals (https://pacylex.com). Current studies have shown that PCLX-001 works differently than other known cancer drugs and has high activity and positive results in breast, lung, bladder and pancreas cancers.
Investigational

GDC-0134

Investigational

WSD-0922

Investigational

ETBX-041

Investigational
Displaying drugs 1326 - 1350 of 1988 in total